Minh Tue Path Group

A major technological pillar in 2026 is the use of Digital Twins of the Human Cell. US informatics firms have created high-fidelity virtual models of various cell types—such as cardiomyocytes for heart disease or neurons for Alzheimer's.

These digital twins allow researchers to conduct millions of "In-Silico" (computer-based) experiments before a single drop of liquid is touched in a lab. Researchers can simulate how a drug molecule will interact with the cell’s complex metabolic pathways, predicting side effects and off-target hits with unprecedented precision. This "Virtual First" philosophy has become a standard requirement in the US FDA's modern drug filing process, as it provides a robust layer of safety data before human exposure.